Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)

China flag China · Delayed Price · Currency is CNY
30.21
-0.51 (-1.66%)
Jun 11, 2026, 2:14 PM CST
Market Cap3.69B +56.6%
Revenue (ttm)688.74M +27.0%
Net Income44.38M +5.9%
EPS0.37 +6.0%
Shares Out 120.00M
PE Ratio83.05
Forward PEn/a
Dividend0.10 (0.32%)
Ex-Dividend Daten/a
Volume1,627,800
Open31.86
Previous Close30.72
Day's Range29.89 - 31.86
52-Week Range29.96 - 81.88
Beta0.07
Analystsn/a
Price Targetn/a
Earnings DateAug 21, 2026

About SHE:300584

Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company’s products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for injection; voglibose tablets, lansoprazole enteric-coated tablets, amlodipine besylate tablets, and glucosamine sulfate effervescent tablets/granules; ... [Read more]

Sector Healthcare
Founded 2003
Employees 553
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300584
Full Company Profile

Financial Performance

In 2025, SHE:300584's revenue was 671.05 million, an increase of 33.05% compared to the previous year's 504.36 million. Earnings were 42.06 million, an increase of 4.58%.

Financial Statements